Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 187 for melanoma

Edit search filters
  1. Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

    Rochester, MN

  2. Pembrolizumab And Ibrutinib In Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

    Rochester, MN

  3. Expanded Access Program With Nivolumab (BMS-936558) In Combination With Ipilimumab (Yervoy®) In Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable Or Metastatic Melanoma (CheckMate 218)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study To Evaluate The Safety And Effectiveness Of Pembrolizumab Compared To Placebo In Resected High-risk Stage II Melanoma Patients

    Jacksonville, FL, Rochester, MN

  5. Ipilimumab Or High-Dose Interferon Alfa-2b In Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed By Surgery

    Jacksonville, FL

  6. A Study To Assess LXH254 In Patients With Previously Treated Unresectable Or Metastatic BRAFV600 Or NRAS Mutant Melanoma

    Rochester, MN

  7. Nab-Paclitaxel And Bevacizumab In Treating Patients With Unresectable Stage IV Melanoma Or Gynecological Cancers

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. E6201 Plus Dabrafenib For The Treatment Of Metastatic Melanoma Central Nervous System Metastases (CNS)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study To Evaluate KIN-2787 In Participants With BRAF And/or NRAS Mutation Positive Solid Tumors

    Jacksonville, FL, Rochester, MN

  10. Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

    Rochester, MN

.

Mayo Clinic Footer